Dai ichi Life Insurance Company Ltd Lowers Stock Position in CVS Health Corporation $CVS

Dai ichi Life Insurance Company Ltd trimmed its holdings in shares of CVS Health Corporation (NYSE:CVS) by 14.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,989 shares of the pharmacy operator’s stock after selling 6,323 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in CVS Health were worth $2,800,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Renaissance Technologies LLC bought a new position in CVS Health in the first quarter worth about $18,900,000. Bollard Group LLC grew its position in shares of CVS Health by 0.9% in the 1st quarter. Bollard Group LLC now owns 17,653 shares of the pharmacy operator’s stock worth $1,268,000 after buying an additional 157 shares during the last quarter. Gabelli Funds LLC grew its position in shares of CVS Health by 1.2% in the 1st quarter. Gabelli Funds LLC now owns 259,700 shares of the pharmacy operator’s stock worth $18,652,000 after buying an additional 3,000 shares during the last quarter. Modern Wealth Management LLC raised its stake in shares of CVS Health by 5.5% during the 1st quarter. Modern Wealth Management LLC now owns 5,030 shares of the pharmacy operator’s stock worth $365,000 after acquiring an additional 260 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in CVS Health by 44.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,219,756 shares of the pharmacy operator’s stock valued at $446,703,000 after acquiring an additional 1,899,932 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is getting a sentiment boost from multiple headlines around its expanded pharmacy services, including nationwide filling of select pet prescriptions and a new service for harder-to-find medications, which could support retail pharmacy traffic and reinforce its convenience-driven growth story.
• Positive Sentiment: Analyst commentary remains constructive, with Zacks calling CVS a top long-term momentum stock and other reports noting a “Moderate Buy” consensus and higher price targets, suggesting Wall Street still sees upside tied to pharmacy, PBM, and Medicare Advantage execution. Article Title
• Positive Sentiment: Options activity also pointed to bullish trading interest, with unusually heavy call buying in CVS, often interpreted as a sign that traders expect further upside or a continued positive trend.
• Neutral Sentiment: A recent report on CVS’s dividend noted that payouts have been unchanged for 10 quarters, framing the dividend as a question for income investors rather than a clear catalyst for the stock.
• Neutral Sentiment: CVS stock has already had a strong run over the past year, and one article highlighted the shares nearing valuation levels that depend heavily on continued operational execution and policy stability.
• Negative Sentiment: Henry Ford Health filed a lawsuit alleging CVS used fraudulent reimbursement practices tied to the 340B drug discount program, which could create legal costs, headline risk, and potential pressure on margins if the claims gain traction. Article Title

Wall Street Analyst Weigh In

Several equities analysts have issued reports on CVS shares. Wall Street Zen raised shares of CVS Health from a “hold” rating to a “buy” rating in a report on Thursday. UBS Group reissued a “buy” rating and issued a $122.00 price objective on shares of CVS Health in a research report on Friday. Mizuho boosted their target price on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Robert W. Baird increased their price target on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Finally, Sanford C. Bernstein boosted their price target on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 12th. Twenty-one investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.67.

Insider Buying and Selling

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Larry Robbins sold 370,462 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. The trade was a 7.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by insiders.

CVS Health Price Performance

Shares of CVS opened at $107.64 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The company’s fifty day moving average price is $100.21 and its 200-day moving average price is $86.12. CVS Health Corporation has a 1-year low of $58.99 and a 1-year high of $110.68. The firm has a market capitalization of $137.34 billion, a PE ratio of 47.42, a price-to-earnings-growth ratio of 1.05 and a beta of 0.61.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities research analysts predict that CVS Health Corporation will post 7.46 EPS for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be issued a dividend of $0.665 per share. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. CVS Health’s payout ratio is 117.18%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.